Tiziana Life Sciences chief medical officer Matthew Davis joins Proactive's Natalie Stoberman to share the latest results from its intranasal foralumab study that's been published in Proceedings of the National Academy of Sciences (PNAS).
Davis says the results show how intranasal foralumab has had similar immune gene expression effects in COVID patients, MS patients and in heathy volunteers that were included in the study. From this study, Davis adds that intranasal foralumab could have a wider opportunity as a treatment for other inflammatory human diseases.
Proactive US
+1 347-449-0879
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.07 |
| Daily Change: | 0.18 20.22 |
| Daily Volume: | 383,851 |
| Market Cap: | US$111.090M |
April 02, 2025 March 25, 2025 March 04, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
